OCT 1·SEC EDGARLow
Higuchi John W. purchased $27K of LPCN
Higuchi John W. purchased 12,561 shares of Lipocine Inc. (LPCN) at $2.16 on 2026-09-28.
StockNASDAQ · US · USDHealthcare · Biotechnology
$LPCN
Lipocine Inc.
Price · $LPCNvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $LPCN in the last 7 days.
Insider · 30dAll trades →
- Buys
- $27K 1 txs
- Sells
- — 0 txs
Higuchi John W.1× · $27K
10b5-1 share of filings0%
Top stories · $LPCNMore →
SEP 11·SEC EDGAR 8-K
Lipocine Inc. and A.G.P./Alliance Global Partners agreed that the Sales Agent’s fee on sales made under that certain Sales Agreement dated April 26, 2024…
Lipocine Inc. (LPCN) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 8, 2026, Lipocine Inc. (the “Company”) and A.G.P./Alliance Global Partners (the “Sales Agent”) agreed that the Sales Agent’s fee on sales made under that certain Sales Agreement dated April 26, 2024 between the Company and the Sales Agent (th
AUG 4·SEC EDGAR 8-K
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
Lipocine Inc. (LPCN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 SALT LAKE CITY, August 4, 2026 — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results
LPCN sentiment & insider activity
Recent LPCN coverage spans corporate actions, financial news and insider activity.
In the last 30 days, LPCN insiders filed 1 SEC Form 4 transaction — 1 purchase ($27K) and no sales. The most active reporter was Higuchi John W. with 1 filing.
What's driving LPCN
Small insider purchase may create modest buying pressure.
The fee increase may slightly reduce gross margins on sales.
The 8-K combines quarterly cash/loss figures with a clinically important Phase 3 readout that is being reframed via a post hoc outlier-site exclusion, plus an FDA guidance meeting scheduled for Q3 2026.
Board expansion and director compensation details are unlikely to change near-term fundamentals, but can modestly affect sentiment and governance expectations.
The Phase 3 trial results for LPCN 1154 were mixed; primary endpoint not met overall, but subgroup analysis shows promise. The company's plans for breakthrough therapy designation could positively influence LPCN stock in the near term.
AlphAI scores every news story that mentions LPCN with an AI model for sentiment and relevance, and aggregates insider trades from Lipocine Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $LPCN
Score
Higuchi John W. purchased $27K of LPCN
Higuchi John W. purchased 12,561 shares of Lipocine Inc. (LPCN) at $2.16 on 2026-09-28.
1 min readLipocine Inc. and A.G.P./Alliance Global Partners agreed that the Sales Agent’s fee on sales made under that certain Sales Agreement dated April 26, 2024…
Lipocine Inc. (LPCN) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 8, 2026, Lipocine Inc. (the “Company”) and A.G.P./Alliance Global Partners (the “Sales Agent”) agreed that the Sales Agent’s fee on sales made under that certain Sales Agreement dated April 26, 2024 between the Company and the Sales Agent (th
1 min readLipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
Lipocine Inc. (LPCN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 SALT LAKE CITY, August 4, 2026 — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results
6 min readLipocine Inc. (LPCN): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Lipocine Inc. (LPCN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Lipocine Inc. Lipocine Appoints Michael J. Grissinger to Board of Directors SALT LAKE CITY, August 3, 2026 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delive
2 min read
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
Lipocine Inc. announced that its Phase 3 trial for LPCN 1154 (oral brexanolone) in postpartum depression (PPD) did not meet its primary endpoint in the overall patient population. However, a post hoc analysis of participants with a history of psychiatric conditions showed nominal statistically significant and clinically meaningful reductions in HAM-D scores compared to placebo. The company plans to evaluate all available options and has applied for breakthrough therapy and fast track designations for LPCN 1154 in this subset of patients.
2 min read
Lipocine Files Prospectus to Enable $50M Stock Offering
Lipocine Inc. has filed a prospectus to enable a stock offering of up to $50 million. This follows a sales agreement made in April 2024 with A.G.P./Alliance Global Partners to periodically sell common stock. The move provides Lipocine with a mechanism to raise additional equity capital to support its corporate and operational needs.
2 min read